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INTRODUCTION 
In February 1991 a discussion paper by the NSW Health Department's Epidemiology 
and Health Services Evaluation Branch (EHSEB) was completed which primarily 
addressed the epidemiology of tuberculosis in NSW1• The paper included a review of 
the international literature on methods of tuberculosis (TB) control, and compared the 
methods used in NSW with those used in other parts of Australia, the United States 
and Britain. 
Key recommendations of this document were that the role and organisation of TB 
Services in NSW be reviewed and that a strategy for NSW be developed which 
addresses TB surveillance, screening, BCG vaccination, chemoprophylaxis, case follow 
up and program evaluation. The NSW TB Advisory Committee also recommended that 
a more in depth appraisal of the epidemiology of TB in NSW be undertaken. 
l . 
l A Review of TB Services in NSW has been prepared by the EHSEB and NSW TB 
J Coordinator, concurrently with the development of this document. Key 
j recommendations from the Review are that: 
• 
• 
• 
• 
• 
• 
• 
all active cases have treatment initiated and ceased by, and be 
discharged from medical care by, a Specialist Physician at the nearest 
Chest Clinic; 
the NSW Infectious Diseases Surveillance System (IDSS) database be 
expanded and be made accessible to Chest Clinics via computer networks 
with Public Health Units, to facilitate surveillance of disease and 
infection, patient management and program evaluation; 
routine screening - of staff, contacts, old inactive cases and migrants on 
Health Undertakings - in localities where Chest Clinic Sisters are not 
based be undertaken by local hospital or Community Health staff; 
Area/ Regional TB coordinators be responsible for routine program 
evaluation and ensuring the implementation of Statewide policies and 
guidelines; 
the NSW TB Coordinator report to the NSW Health Department on TB 
program indicators for the State; 
updated State policies and guidelines for Mantoux testing, contact 
tracing, migrant and refugee follow up, BCG vaccination and screening 
of health care workers be distributed to NSW health services in a 
'Policies and Procedures Manual'; and 
• consensus guidelines be developed, through consultation with clinicians, 
related to first line drug regimens and indications for chemoprophylaxis, 
the role of supervised chemotherapy and duration of case followup. 
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Recommendations from the 1991 discussion paper and the 1992 Review of TB Services 
have been incorporated into this Strategy for the Control of TB in NSW. 
This document addresses four major methods of TB control: disease containment, case 
prevention, surveillance and program evaluation. 
• 
• 
• 
• 
Disease containment 
Early identification and adequate treatment of cases of infectious TB are 
the most important measures to prevent spread of the disease. The 
major obstacle to disease containment is the interruption of and/ or 
failure to complete therapy with an appropriate drug regimen2• The two 
main causes of treatment failure are inappropriate combinations of 
drugs, dosages and duration and poor compliance (due to inadequate 
supervision or communication and social or medical host factors such as 
alcohol, drugs, poor nutrition, homelessness). 
Case prevention 
The main case prevention strategy is screening for, and treatment of, TB 
infection in high risk groups. No matter how efficient case finding, 
diagnosis and treatment are, the development of disease in those already 
infected can only be prevented by appropriate chemoprophylaxis3• The 
associated risks - side effects and possible emergence of drug resistant 
strains - must be weighed against the potential benefits. 
Surveillance 
Timely identification and notification of confirmed and suspected cases 
facilitates early treatment and preventive intervention. Surveillance is 
essential for estimating incidence, distribution and trends of disease and 
infection and for plauning services rationally. In low incidence countries, 
the number and trends in bacteriologically positive cases is the most 
useful parameter of the epidemiology of TB. The risk of infection is only 
a useful indicator with large sample sizes which provide reliable 
estimates. Infection surveillance requires careful strategic planning of 
screening in high risk populations. 
Program evaluation 
The monitoring of parameters related to disease containment, case 
prevention and surveillance activities provides important information for: 
• 
• 
evaluating program performance 
assessing epidemiological trends: eg the incidence of 
Mantoux conversion in contacts reflects the rate of transmission 
of TB in the population. 
• 
• 
• 
evaluating the effectiveness of interventions: eg although the 
efficacy of modern treatment regimens under controlled trial 
conditions is well established, there are few data available on the 
effectiveness and efficiency of treatment under routine conditions 
in low incidence countries. 
program planning: Program evaluation, research and monitoring 
of epidemiological trends should guide program plauning, eg 
screening programs should be regularly evaluated to assess their 
worth, as screening is generally recommended only where the rate 
of infection is greater than one per cent4• 
patient management: In the case of TB few data beyond those 
necessary for patient management are required for routine 
program evaluation. 
. This document has three parts. The first part provides an overview of the epidemiology 
' of TB in NSW. The second part defines the goals, targets and implementation 
· indicators for the NSW TB Control Strategy. The third part contains policies and 
guidelines for TB Services, which were endorsed by a consensus meeting of Chest 
Clinic Staff, Respiratory, Public Health and Infectious Disease Physicians in October, 
1992. 
The proposed implementation indicators - for each of the four control methods and for 
TB Services themselves - are intended to provide strategic direction and a means of 
monitoring progress towards attaining the goals and targets. Each implementation 
indicator includes a timeline and the person(s) responsible for ensuring its 
achievement. 
This document does not attempt to review the current state of international knowledge 
. of TB control. Such a review was the subject of the 1991 discussion paper and readers 
should refer to that document1• Recommendations from that review have been 
incorporated into the strategies and policies. 
The rationale behind the proposed implementation indicators and policies is that more 
effective and efficient use of existing prevention and control methods and technologies 
should lead to significant improvements in TB control. 
The development of new preventive, diagnostic and treatment technologies will 
expedite these improvements. Although not specifically addressed by this document, 
the NSW Health Department and associated bodies, eg Institute for Clinical Pathology 
and Medical Research (ICPMR), should encourage the development, evaluation and 
implementation of rapid diagnostic techniques, improved screening methods, short 
duration drug regimens and treatments for drug resistant strains. This research 
should be undertaken in cooperation with the National Health and Medical Research 
Council (NHMRC) and World Health Organization (WHO) sponsored programs. 
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1. EPIDEMIOLOGY 
1.1 ACTIVE DISEASE NOTIFICATION 
In NSW 393 active TB cases were diagnosed and reported in 1991. Of these, nine 
(2.3%) were cases of reactivated TB. Of 383 new cases, 289 (76%) had pulmonary 
disease. 
Notifications of reactivated cases have continued to decline steadily from 0.6 per 100 
OOO in 1979 to 0.3 in 1986 and 0.2 per 100,000 in 1991. The case load of reactivated 
disease has also declined. In 1975 9.8% (51) of the notified cases of pulmonary disease 
were reactivations5• In 1991 2.7% (eight) of notified cases of pulmonary disease were 
reactivations. Of these eight reactivated cases, five were Australian born (all aged over 
45), one was Asian born (aged 25-34) and two were born in Europe (both aged over 45). 
(Until 1992 a reactivation was defined as a case of active TB who had previously 
received a full course of treatment in NSW and been declared cured.) In NSW between 1963 and 1991 notifications of active disease declined from 30.5 to 
6.5 per 100,000 for new cases and 3.5 to 0.15 per 100,000 for reactivated cases (Figure 
1). The notification rate of smear positive cases in 1991 was 2.8 per 100,000. 
Moderate decreases occurred in notifications of new cases of TB in NSW in the early 
1980s, froin a rate of 11.1 per 100,000 in 1979 to 5.2 per 100,000 in 1986. Between 
1989 and 1991 there was a slight increase, from 5.8 new cases per 100,000 to 6.5 per 
100,000. 
{ In 1991, of the 260 new pulmonary cases for whom direct sputum smear results were 
; recorded, 132 (51%) were smear positive. Smear negativity is more co=on in Asian 
j born cases than Australian born cases", proportions having smear positive disease 
, being 58% and 48% respectively in 199L · 
The decline in new cases since 1963 is almost entirely accounted for by the decline in 
new pulmonary disease from a rate of 28.7 to 4.9 per 100,000 in 1991 (Figure 2). ·' 
Over the same period notifications of new extrapulmonary disease have ranged 
between a maximum of 2.3 per 100,000 in 1973 and a minimum of 1.0 per 100,000 in I 
1985. A moderate increase in notifications of new extrapulmonary disease has occurred J 
since 1985. In 1991 the notification rate of new extrapulmonary disease was 1.6 per 
100,000. 
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1.2 MORTALITY RATES 
Mortality due to TB in Australia has fallen steadily this century5. This fall was 
accelerated by the introduction of effective chemotherapy in about 1954. The majority 
of deaths occur in the elderly, many of whom die with, rather than from, TB6• 
The death rate from TB in NSW declined from 1.40 per 100,000 people in 1970 to 0.54 
per 100,000 in 1988. 
Over the period 1989 to 1991 less than 1% of all TB case notifications were from death 
certification (ie 'delay of diagnosis until death'). 
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1.3 CENTRAL NERVOUS SYSTEM (CNS) DISEASE 
For 1988/89 the incidence of TB CNS infections was 0.35 per 100,000 population. The 
highest age specific incidence was in 35-44 year olds, being 1.4 per 100,000. Of the 20 
cases with TB infection of the CNS, 12 (60%) were in the age group 35-44. There was 
only one child aged less than five years with TB of the CNS. 
1.4 DRUG RESISTANCE RATES 
Asian immigrants are considered at particular risk of harbouring drug resistant 
tubercle bacilli because of the likelihood of inadequate, interrupted chemotherapy, 
usually with one or two drugs, due to the high relative costs of anti-TB drugs in Asia". 
High rates of drug resistance strains have also been reported overseas in those with 
HIV-TB coinfection2• 
In 1991 18 new TB cases (4.7%) were resistant to isoniazid, five (1.3%) were resistant 
to rifampicin, 30 (7.8%) were resistant to streptomycin and one case (0.3%) was 
resistant to ethambutol. Eight new cases were resistant to two drugs (Australian born: 
1, Asian born: 4, Middle East born: 3). Two new cases were resistant to three drugs 
(Asian born: 2). 
Of the eight reactivated TB cases in 1991, only one was drug resistant. This case, who 
was Australian born, was resistant to two drugs. Of the 10 cases of TB-HIV 
coinfection, two were resistant to one drug and one was resistant to two drugs. 
1.5 INFECTION PREVALENCE AND INCIDENCE 
Data on infection prevalence and incidence rates in subpopulations in NSW are 
limited. 
1.6 RISK FACTORS 
TB morbidity in a population depends upon the risk of infection and the risk of disease 
following infection. One new TB case on average leads to less than one new infectious 
case10 so rates of disease in a stable community should naturally decline. 
Some groups have a higher incidence of TB than the general population due to a 
higher prevalence of infection, or higher risk of developing the disease once infected. 
Most new cases of TB arise from people with latent rather than new infections10• There 
is often a long latent period between infection and development of TB. It is estimated 
that more than 90% of people with disease have harboured TB infection for at least a 
year; the remaining 10% have immediate progression of recently acquired infection 11. 
Age 
The risk of TB infection is associated with increasing age in all races and in both 
sexes10• The risk of progression to disease is highest in infants, young adults and the 
. elderly10•12• TB infection acquired in infancy and adolescence carries a high risk of 
rapid progression to disease13; if disease develops, a more serious form (for example 
meningitis or miliary disease) is more likely to occur11• The lifetime risk of TB disease 
for infected children is up to 10%'0• The prevalence of disease generally rises steeply 
with age, particularly for bacteriologically proven disease". Persons over age 50 with 
unrecognised smear-positive disease are considered major public health risks". 
1991 NSW notifications show an increasing trend with age, with minor peaks in the 
age groups 0-4 years and 25-44 years (Figure 3). The highest incidence is in those aged 
· more than 65 with a rate of 13.7 per 100,000 for new cases and 0.6 per 100,000 for 
reactivated cases. 
Fig a: ACTIVE TB NOTIFICATIONS BY AGE 
A recent survey of police recruits in NSW found a Mantoux positivity rate on 
employment of 11%7• In those who had not been previously BCG vaccinated the 
Mantoux positivity rate was 7%. A Mantoux reaction of 5mm or more was considered a j 
positive result. Using a cut-off point for a positive reaction of 10mm or more, 4% of 
those who had not previously received BCG vaccination were Mantoux positive. These 
results are considered generalisable to the NSW population. 
NSW - 1991 
20 ···············----------------------·-----·------------·---- ----------
15 ----------------------------------------·--·------------·---- ----------
Preliminary results from a screening survey of Year 8 schoolchildren in Central/ 
Southern Sydney, an area with a high migrant population, show a Mantoux positivity 
rate of more than 12%8 • In children who had had previous BCG vaccination a 
Mantoux reaction of 15mm, and in non-vaccinated children a Mantoux reaction of 
10mm, was considered positive. Other recent screenings in Sydney of Year 4 and 
Kindergarten children have found TB infection prevalence rates of 16% and 13% 
respectively". 
Overseas data have shown that a 1 % annual risk of infection in an unvaccinated 
population represents an annual smear positive case rate of about 50 per 100,000 
population•. Extrapolating from this, we estimate that the annual risk of infection in 
NSW is between 0.04% and 0.05%. 
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Aboriginality 
The active TB notification rate for Aborigines and Torres Strait Islanders of over 50 
per 100,000 has been reported in Australia". Among Aboriginal communities in South 
Australia the infection prevalence rate in the late 1980s was 16.8% with a range of 
7.7%-30.8%9• 
In people known to be Aboriginal in NSW the annual notification rate of TB was 3.6-
7.2 per 100,000 population in 1986-88. In 1991 only two cases of TB were reported in 
Aboriginals. 
NEW TUBERCULOSIS CASES BY PLACE OF BIRTH 
Fig 4: 
NSW - 1970-1988 
number rate/100,000 600 ;;..::.;.__:_: __________________ ---, 30 
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D overseas born rate 
Country of birth and ethnicity 
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-+- Australia born cases 
• Australia born rate 
High rates of infection are found in ethnic groups and immigrants from high 
prevalence TB countries". Most countries in Asia, Africa and Latin America are high 
prevalence countries. In Australia only immigrants from the USA, Canada, New 
Zealand and Scandinavia have incidence rates as low as, or lower, than the Australian 
born population". Diseas.e rates in immigrants are highest in the first few years after 
arrival. Ethnic groups tend to have a higher incidence of active disease especially in 
the younger age groups (irrespective of country of birth)10• 
Data from census years show that notification rates of disease in NSW among people 
born in Australia have fallen steadily since 1971, and among those born overseas only 
since 1981 (Figure 4). From 1986 to 1988, among people born in Australia and not 
recorded as Aboriginal, the notification rate of TB was 1.9-2.2 per 100,000 per year. 
Notification rates of TB among people born in South East Asia exceeded 200 per 
100,000 population. Rates of mycobacterial disease for selected countries of birth are 
shown in Figure 5. 
8 
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Fig 5: NEW MYCOBACTERIAL DISEASE NOTIFICATION 
BY COUNTRY OF BIRTH - NSW 1986-1988 
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In 1970, 80% of notified cases were born in Australia, but by 1988, this figure had 
fallen to 26%. In 1991 31% of new cases were born in Australia. The age groups with 
the highest proportion of new cases who were Australian born were the under five and 
over 65 year age groups, being 75% and 50% respectively (Figure 6). 
In NSW most cases of paediatric TB occur in children either born overseas or born in 
Australia of Non-English Speaking Backgrounds (NESB). Of cases aged less than 15 
years notified in 1991, 61% were born in Australia. However, of the Australian born 
cases, 74% were from NESB. Of these 79% were from Asian backgrounds. 
The high notification rate of TB in the age group 25-44 years in NSW is largely 
accounted for by immigrants, with only 19% of cases in this age group being 
Australian-born in 1991. In contrast, of those aged over 65 years 48% were Australian 
born and a total of 60% were from English-speaking backgrounds. 
For 1989-1991, among cases not born in Australia, 22% were notified within 12 
months, 50% within five years and 79% within 15 years of arrival in Australia (Figure 
7). As the proportion of cases declines with years after arrival, 'recent arrival' is a risk 
factor for TB. 
For 1990-1991 the Mantoux positivity rate in Indochinese screened by the NSW 
refugee screening program was 46% in those who had been previously BCG vaccinated 
and 40% in those who had not been previously BCG vaccinated15• The rates of chest 
x-ray abnormalities detected by migrant/refugee screening in NSW in 1990 for 
Vietnamese, Laotians, Kampucheans and Latin Americans were 116.6, 48.0, 95.2 and 
105.0 per 100,000 population respectively16• 
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F10 s: TB CASES BORN IN AUSTRAL IA 
AND OVERSEAS BY AGE NSW 1991 
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Sex 
The risk of TB infection and pulmonary disease is higher in males than females6·'0• In 
1991 in NSW the male to female ratio for pulmonary disease was 1.5 : 1 and for 
~apulmonary disease the ratio was 1 : Ll. The recent Mantoux screening survey of 
police recruits in NSW estimated that, 7.7% of males and 2.9% of females have 
tuberculous infection, a ratio of 2. 7 ; 17• 
Between 1963 and 1991 the proportion of notified cases who were male declined from 
70% to 56%. Over the same period among Australian born people, the proportion of 
cases who were male declined to a lesser degree, from 70% to 65%. In 1991 the 
proportion of cases born overseas who were male was 53%. The more rapid decline in 
disease among males compared with females is therefore largely an effect of 
immigration. 
The notification rate of disease in NSW males is twice that of females in the older age 
groups. In 1991 the notification rate of active disease in those aged more than 65 years 
was 20.1 per 100,000 for males and 10.1 for females (Figure 8). 
Fig B: ACTIVE TB I\OTIFICATICNS BY AGE 
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Close contacts 
High infection rates are found in close contacts of active pulmonary TB cases. One 
quarter of contacts of people with TB develop infection with those in close contact 
being at greatest risk'°·". Up to 2% of contacts of newly discovered TB cases have 
developed TB disease by their first examination13• The risk to contacts of 
extrapulmonary cases is 1%17• 
11 
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Infected contacts are more likely to develop disease if infected by a culture positive 
case with a positive direct sputum smear than a case with a negative smear. The risk 
of infection depends largely on the density of Mycobacterium tuberculosis in droplets 
expelled into the air by a person with TB and the time a susceptible person is exposed 
to that air. The density of infected droplets in the air depends on the frequency of 
coughing, the density of bacilli in the sputum and the volume of the air space. 
In NSW in 1991 3.6% of notified active cases were known contacts of other reported 
cases. 
Human Immunodeficiency Virus (HIV) infection 
Other medical risk factors 
The risk of progression of infection to disease is high in immunosuppressed people. 
Silicosis, malignant lymphomas, lung cancer, lymphosarcoma, reticulum cell sarcoma, 
head and neck cancers, haemophilia, end stage renal failure and patients on 
haemodialysis are associated with an increased risk of TB10• Low body weight, 
gastrectomy, diabetes, corticosteroid therapy, and HLA types All, B15 and DR2 have 
also been implicated'". Smokers, particularly those with chronic lung disease, are at 
increased risk". 
Long term residential facilities 
In US prisons TB is a major health problem and is increasing. The incidence among 
The increased incidence of TB overseas, notably in the US in recent years, is partly New York State prison inmates increased from 15.4 per 100,000 in 1976-1978 to 105.5 
due to an excess of active disease in those with TB-HIV coinfection and partly due to per 100,000 in 1986, 56% of whom were infected with HIV'". Eleven outbreaks in US 
increasing poverty and homelessness. prisons were reported in the period 1985-198818• In the US the incidence of TB in 
nursing home residents is higher than among elderly people living in the community 
Although Mycobacterium avium complex is the commonest mycobacterial species (39.2 per 100,000 versus 21.5 per 100,000)19• 
isolated from people with acquired immunodeficiency syndrome (AIDS), infection of 
people with AIDS with Mycobacterium tuberculosis has the potential for more serious In NSW for the period 1989-1991, there were five notifications of active disease in 
health consequences in the general community, because of its capacity to infect people people identifiable as being resident in nursing homes, three notifications from 
with normal immune systems. TB-HIV coinfection is characterised by more widespread psychiatric institutions and one notification from gaol. 
TB disease with unusual clinical features which makes diagnosis difficult. 
survey to estimate the prevalence of infection in new prisoners at Tamworth gaol is 
In NSW at present the notification rate of TB-HIV coinfection is low. In 1991 only ten · currently underway. 
cases of TB (2.5% of all NSW notifications) were recorded in HIV positive people 
(Figure 9). Homelessness 
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High prevalence rates of TB disease (1.6%-6.8%) and TB infection (18%-51%) have 
been reported for homeless people overseas14• In NSW for the period 1989-1991 three 
cases were notified from 'hostels for the homeless' and one case was recorded as being 
of 'no fixed address'. Chest x-ray screening of homeless men attending 5 hostels in 
astern Sydney during 1991 and 1992 showed that 15-25% of residents had results 
. consistent with active or inactive TB. 
rug and alcohol dependency 
rug users and alcohol dependent people are at increased risk of TB6 • Between 1989 
d 1991 in NSW two notified cases were identifiable as being resident in alcohol 
ehabilitation centres. 
ccupation 
n the US estimates of the annual incidence of infection in health care workers 
HCWs) in recent years have varied between 1.5% and 10.3%20• In South Australia 
he prevalence of TB infection in HCWs under 45 years is 20%-30%9 • Research 
aboratory staff handling infected material are considered at particular risk6• 
13 
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2.1 
STRATEGIES 
GOALS AND TARGETS 
Occupation data are available for 951 of the 1044 notified cases (91%) between 1989 2 • 
and 1991. Thirty seven cases (4%) were identifiable as HCWs. Of these 37 cases, 28 
(76%) were born overseas. Of the nine Australian born cases, four were medical 
practitioners (including one retired and two pathologists) and five were nurses 
(including two retired and one a pathology nurse). GOALS 
Other 'occupational groups' considered at high risk are the unemployed and 
pensioners6• The incidence of TB is strongly associated with socioeconomic status and 
income". 
Old healed TB 
By 2001 
• To reduce the annual incidence of active TB disease to 2 per 100,000 
population. 
By 1995 
Those with old healed TB ·(abnormal chest x-rays with fibrotic lesions consistent with _ • 
old healed TB) are at increased risk of active TB10•11• 
To reduce the annual incidence of smear positive TB to 2 per 100,000 
population. 
TARGETS 
Geographical area 
Disease containment 
The notification rate of new TB disease is high in the Sydney metropolitan area and i 
low in rural areas. The highest rates in 1991 were recorded for Central Sydney (15.4 By 1995: 
per 100,000) and South West Sydney Area (12.7 per 100,000) (Figure 10). 
Fig 10: ACTIVE TB NOTIFICATIONS BY HEALTH 
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ratell00,000 
18.....-~--'-~~~~~~~~~~~~~~~~~~--, 
16 ······-······-·······-·······-·······-··-··········-·······-·······-··············· 
14 ················-·······-····-········································-·-····-··· 
12 
10 
B 
6 
4 
2 
O CSA ESA SSA SWS WSA WEN NSA CCA ILL HUN NCR NER OFR CWR SWR SER 
Areal Region 
• To detect 95% of all smear positive cases. 
• 
• 
To ensure that 100% of smear positive cases are commenced on an appropriate 
multidrug regimen within two weeks of diagnosis. 
To ensure that 99% of smear positive cases have taken chemotherapy 
continuously for six months after commencing treatment. 
By 2001: 
• 
• 
To detect 99% of all smear positive cases. 
To cure 99% of all smear positive cases . 
Case prevention 
By 1995 
• 
• 
To ensure that 95% of close contacts of smear positive cases are examined 
within ten days of index case diagnosis. 
To ensure that 90% of infected people commenced on chemoprophylaxis have 
taken the drug(s) continuously for six months after commencing treatment. 
Notes: CSA= Central Sydney; ESA"' East.em Sydney; SSA= Southern Sydney; SWS = South Western Sydney; WSA = Western Sydney; WEN = Surveillance 
Wentworth; NSA"' Northern Sydney; CCA = Central Coast; ILL= lllawarra; HUN = Hunter; NCR: North Coast; NER = New England &agion; 
OFR"" Onma & Far West Region; CWR = Central West &gion; SWR = South West Region; SER= South East Region. 
By 1995 
• To ensure that 100% of cases are notified . 
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2.2 IMPLEMENTATION INDICATORS 
Disease containment By 1993 
By 1993 
By 1993 
By 1993 
By 1993 
By 1993 
By 1994 
By 1994 
By 1994 
Tuberculosis Advisory Committee (TBAC) to produce consensus 
guidelines, including a Departmental circular, on TB treatment and case 
follow up, which are endorsed by the Thoracic Society of Australia and 
New Zealand (TSANZ) and National Health and Medical Research 
Council (NHMRC). See Chemotherapy, Chapter 3.11. 
Epidemiology Branch (EHSEB) and Health Public Affairs (NSW Health , 
Department) to produce TB educational materials in a number of : 
community languages - promoting early diagnosis and treatment, contact 
follow up and access to TB services. 
NSW TB Coordinator to make annual projections of drug needs for the 
State, based on surveillance of disease and drug resistance rates, and to 
communicate these to suppliers via the Pharmaceutical Services Branch. 
NSW TB Coordinator to ensure that at least one teaching hospital is 
established as a site for essential stocks - particularly drugs - and that 
the site and stocks are regularly monitored. 
Area TB Coordinators to establish local advisory groups, composed of • 
representatives of high risk populations and agencies providing health 
(including general practitioners), housing and welfare services to these 
populations. These local groups will advise on priorities and the 
development, implementation and evaluation of strategies appropriate to 
high risk population groups, aimed at increasing awareness of TB, 
facilitating access to care and improving compliance with treatment. 
NSW TB Coordinator/ EHSEB to evaluate the acceptability and 
accessibility of TB Services, from a sociocultural perspective, and to 
implement and evaluate change as required. 
Area/ NSW TB Coordinators to develop and evaluate specific strategies 
for improving compliance with treatment regimens for each identified 
high risk group. These strategies should be sensitive and responsive to 
By 1993 
By 1993 
By 1993 
people's beliefs, cultures and environments and reflect an understanding By 1993 
of the difficulties associated with behavioural change. 
EHSEB to evaluate and report on risk factors for treatment failure: 
interrupted therapy, failure to complete therapy, relapse and chronicity. By 1993 
Case prevention 
By 1993 NSW TB Coordinator/ EHSEB to produce Departmental circulars of By 1993 
guidelines for Mantoux testing, contact tracing, BCG vaccination, and 
follow up of refugees and migrants on Health Undertakings (TBUs). See 
16 
Chapters 3.2, 3.3, 3.5, 3.6 and 3.9 for guidelines. 
TBAC to produce consensus guidelines, (including a Departmental 
circular), on chemoprophylaxis, including indications and recommended 
first line drug regimens, which are endorsed by the TSANZ and 
NHMRC. See Chemoprophylaxis, Chapter 3.10. 
Public Health Unit (PHU) Directors to ensure that: 
• 
• 
• 
95% of all confirmed and presumptive diagnoses of TB are 
notified within five working days of diagnosis by : 
• Improving liaison with Clinicians - Respiratory, Infectious 
Disease, HIV/AIDS Clinicians and Paediatricians and 
private practitioners. They should be made aware of the 
notification criteria for TB which includes the presumptive 
diagnosis. See Appendix 1 for case definitions of 
tuberculosis. 
• Encouraging doctors and laboratories to notify by 
telephone. 
Delays in notification of more than five days are investigated and 
action is taken to prevent similar delays in the future. 
Chest Clinic Sisters (CCS) are phoned immediately on receipt of 
notifications and copies of doctor and laboratory notifications are 
forwarded by mail (pending networking of PHUs and Chest 
Clinics). 
Area TB Coordinators to ensure that the completeness of notifications is 
routinely evaluated by review of pharmacy and bacteriology records 
within all major hospitals for unnotified TB patients. 
NSW and Area/ Regional TB Coordinators to ensure that the recording 
and interpretation of Mantoux tests is standardised. See Mantoux 
testing, Chapter 3.3. 
Area/ Regional TB Coordinators and PHU Directors to ensure that 90% 
of close contacts of smear positive cases are examined within seven days 
of diagnosis for child contacts and ten days for adult contacts. 
EHSEB to assess the risk of infection in 'high risk' health care workers, 
by analysis of retrospective and/ or prospective data. See Health Care 
Worker Screening and Protection, Chapter 3.4. 
TBAC/ EHSEB to review and update Health Department policy 
regarding routine health care worker screening and BCG vaccination. 
See Chapter 3.4. 
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By 1993 
By 1993 
By 1994 
By 1994 
By 1994 
By 1994 
By 1994 
By 1994 
EHSEB to assess the need for modification of TBU follow up and refugee 
follow up protocols, by analysis of available data. See Chapters 3.5 and . 
3.6. 
EHSEB to report on the risk of infection and for disease in the following 
populations: new prisoners, the homeless and nursing home residents. 
See Screening, Chapter 3.1 for discussion of the rationale for selecting 
target groups for screening. 
EHSEB to report on the risk of infection and disease in intravenous drug 
users and HIV seropositive people. See Chapter 3.1. 
EHSEB to report on the risk of infection and disease in Aboriginals. 
EHSEB to assess the potential value of periodic Mantoux screening of 
children in 'high risk' areas, by cost effectiveness analysis. 
By 1993 
By 1993 
By 1993 
By 1994 
By 1995 
EHSEB to assess the value of refugee screening, by cost effectiveness , 
" analysis using available data. '.i 
NSW TB Coordinator/ EHSEB to participate in national collaborative 
study of overseas born TB cases notified in 1991, with the aim of 
evaluating the effectiveness of follow up of migrants on TB Us. 
EHSEB to assess the need for modification of contact tracing guidelines, 
by analysis of available data. 
By 1995 
Area/ Regional TB Coordinators to report to the NSW TB Coordinator on 
investigations of contacts of infectious cases within institutions (for 
example, nursing homes, schools, hospitals, prisons, hostels for the 
homeless, workplace) within one month of notification. 
Area/ Regional TB Coordinators to report annually to the NSW TB 
Coordinator on infection rates for all screened population groups. 
NSW TB Coordinator/ EHSEB to undertake validation studies of TB 
notifications every two years, by review of selected records systems (for 
example laboratory reports, pharmacy reports, death certificates). 
EHSEB to write a program which translates computerised information 
from ICPMR mycobacteriology laboratory into a form compatible with 
the IDSS. 
At least one Health Area with a high incidence of TB to undertake 
periodic (three-five yearly) surveys of the prevalence of tuberculous 
infection in children of various ages. 
All Area Health Services to provide access for Chest Clinics to the 
expanded version of IDSS, by computer networking of Chest Clinics and 
PHUs. Chest Clinics to be responsible for using the network IDSS to 
update notification details, monitor infection rates in high risk 
populations and for program evaluation. 
Program evaluation 
Surveillance 
By 1993 
By 1993 
By 1993 
By 1993 
EHSEB to expand the NSW Infectious Diseases Surveillance System 
(IDSS) database to include additional data related to TB cases, eg drug 
sensitivities, source of discovery (see Appendix 2). 
EHSEB to expand the NSW IDSS database to include data related to 
infection: 
• contact follow up - eg new infections detected (contacts relational 
file) 
• other screening - eg. infections detected in health care workers 
and other high risk populations (screening module). 
EHSEB to link the NSW IDSS database with Australian Bureau of 
By 1993 
By 1993 
Statistics mortality data for estimation of prevalence of active and By 1993 
inactive TB disease at death and hence the case detection ratio. 
NSW TB Coordinator/ EHSEB to report annually at the State level on 
indicators of TB disease and infection: rates of TB disease (and smear 
positive disease), hospitalisation and mortality; reactivation; HIV-TB co-
infection; drug resistance; TB meningitis (children aged less than five); By 1994 
and infection rates for all screened population groups. See Appendix 3 
for proposed set of disease and infection surveillance indicators. 
18 
TBAC to agree upon a core set of program evaluation indicators for 
Areas/Regions and the State. See Appendix 3 for proposed set of program 
evaluation indicators. 
EHSEB to expand the NSW IDSS database to include additional case 
follow up details, to facilitate program evaluation and patient 
management, eg related to drugs prescribed, duration and interruption 
of chemotherapy, and bacteriologic conversion (TB case module). These 
additional details should directly relate to the core set of program 
evaluation indicators (see Appendix 2). 
The expanded IDSS should include a programmed reporting facility 
which generates program evaluation indicators for specified periods of 
case notifications by cohort analysis. 
Area/ Regional TB Coordinators to report quarterly to the NSW TB 
Coordinator on program evaluation indicators for case management and 
follow up related to: delay in diagnosis and notification; initiation of 
appropriate drug regimen; drug continuity and completion; treatment 
failure; cure; case fatality (see Appendix 3). 
EHSEB to expand the NSW IDSS database to include information from 
screening, to facilitate program evaluation and patient management: 
19 
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By 1994 
By 1994 
Services 
By 1993 
By 1993 
By 1993 
By 1993 
)i 
By 1993 
I 
• contact tracing details eg time until follow up, new infections 
detected (contacts relational file/ screening module). 
• other screening data eg drugs prescribed, duration and 
interruption of chemoprophylaxis (screening module). 
Area/ Regional TB Coordinators to report annually to the NSW TB 
Coordinator on program evaluation indicators for screening related to: 
delay in examination of contacts; location of contacts; infection rates for 
all screened populations; initiation of chemoprophylaxis; drug continuity 
and completion (see Appendix 3). 
NSW TB Coordinator to report annually to EHSEB on program 
evaluation indicators for case management/ follow up and screening. 
NSW TB Coordinator/ PHU · Directors to nominate TB coordinators for 
each Area/ Region, who will be responsible for: 
. By 1993 
• program evaluation and quality assurance, and By 1993 
• ensuring and monitoring the implementation of Statewide policies 
and guidelines, recommendations from the NSW Review of TB By 1993 
Services 1992 and other responsibilities outlined in this 
document. 
NSW TB Coordinator/ EHSEB to incorporate updated Statewide 
guidelines and policies related to TB control into a standard 'Policies and 
Procedures Manual', which is distributed to NSW Chest Clinics, PHUs 
and hospitals, as well as Regional Community Health Services. 
Area/ Regional Health Services should aim to have 
• Chest Clinics staffed with Physicians with special training in TB, 
and 
• in rural areas where Physicians with training in TB are no 
available, all active cases to have treatment initiated and cease 
by and be discharged from medical care by such a Physician fro 
the most accessible Chest Clinic. 
Area/ Regional Health Services to ensure that all Area hospitals, and 
major Regional hospitals or Community Health Services, have at leas 
one registered nurse trained in routine Mantoux testing and BC 
vaccination of staff and patients. 
Area/ Regional Health Services to ensure that: 
20 
y 1994 
y 1994 
• 
• 
• 
'satellite' Clinics (run by CCS at locations remote from their base 
Clinic) are rationalised, 
in these small rural localities at least one nominated registered 
nurse (hospital and/ or community based) is trained in and 
performs all basic TB related duties (Mantoux testing; BCG 
vaccination; supervision of anti-TB chemotherapy; routine follow 
up of contacts, inactive cases and migrants on TBUs), and 
the routine follow up of inactive cases, migrants on TBUs and 
contacts who live remote from a Regional Chest Clinic is 
coordinated and supervised by the nearest CCS. 
NSW and Area/ Regional TB Coordinators to develop inservice training 
modules for health care workers (and workers in long term care 
facilities) about the risks of TB transmission, signs and symptoms, 
methods of diagnosis, procedures for minimising risk and accessing TB 
Services. 
NSW TB Coordinator/ EHSEB to develop program evaluation training 
modules and guidelines for Area/ Regional TB Coordinators. 
Area/Regional TB Coordinators/Health Services to ensure that 
appropriate mechanisms are in place within hospitals to facilitate 
effective liaison and coordination between Infectious Diseases, HIV/AIDS 
and Chest Clinic medical and nursing staff. 
NSW TB Coordinator to annually update the NSW TB 'Policies and 
Procedures Manual'. 
Area TB Coordinators/ Area Health Services to ensure that: 
• 
• 
staff who provide TB Services receive appropriate training to 
facilitate effective communication with high risk groups, and 
staff are culturally sensitive to the populations being served . 
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3. POLICIES 
8.1 SCREENING · TARGET GROUPS 
• 
• 
• 
• 
Due to the low yield, mass population screening is not justifiable except for 
subgroups with high rates of infection. The rationale is to identify those who 
would benefit from chemoprophylaxis (or chemotherapy). Screening, by Mantoux 
testing, is generally recommended where the rate of infection is greater than 
1%'. 
The predictive value of Mantoux tests is low in populations with a low , 
prevalence of infection. This means that in low risk populations, eg the general i 
population or distant contacts (eg workmates) of cases of low infectiousness, a 
large proportion ofMantoux positive people will not be truly infected. 
AB rates of disease decrease, the value of continued screening should be 
regularly assessed. 
Screening chest x-rays are rarely justified, except when: 
a) The objective is to identify those with current pulmonary disease 
and the administration of chemoprophylaxis to infected people is 
not possible". Those in hostels for the homeless are suitable for 
screening by chest x-rays (and possibly sputum smears). 
b) There is a high probability of false negative Mantoux reactions, eg 
in immunosuppressed people. Therefore, a high index of clinical 
suspicion of pulmonary and extrapulmonary disease should be 
maintained and appropriate investigations performed for people 
with clinical AIDS or other HIV related disease, regardless of the 
results of Mantoux testing''. 
• In NSW the following groups should be screened by Mantoux tests (unless 
otherwise indicated) on a routine or periodic basis: 
(i) Routine screening 
(ii) 
• Close contacts of people known or suspected to have clinical TB 
• People with medical risk factors for TB 
• People with HIV infection 
• Health care workers/ students at the commencement o 
employment 
• Immigrants (migrants and refugees) from high prevalenc 
countries 
Periodic screening 
• Residents of hostels for the homeless - six monthly chest x-ra 
screening 
22 
• 
• 'High risk' HCWs - 12 to 24 monthly Mantoux tests (depending 
upon estimated risk). 
To identify other high risk groups in NSW, baseline data should be obtained to 
estimate risk and hence evaluate the need for screening on a routine or periodic 
basis. The risk should be estimated either by baseline screening surveys or 
collation and analysis of available data, as indicated: 
(i) Routine screening: 
(ii) 
• 
• 
.. 
Prison inmates on admission - Mantoux screening survey 
Nursing home residents on admission - chest x-ray screening 
survey 
Injecting drug users - Mantoux screening survey · 
Periodic surveys (frequency depending on the estimated risk) 
• 
• 
'Medium risk' HCWs - Baseline screening surveys and/ or 
collation and analysis of available data (See Chapter 3.4) 
Aborigines - Mantoux screening survey 
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8.2 
A. 
CONTACT TRACING AND FOLLOW UP 
Aims 
The aims of contact tracing are: 
1. to identify those infected by the index case, and/ or 
2. to identify a source of infection for the index case. 
B. Notification of cases to Chest Clinic staff 
c. 
PHUs should immediately report case notifications to the nearest Chest Clinic, 
by phone initially, followed up by sending copies of notifications. ('Notifications' 
include all doctor notifications of TB and laboratory notifications of 
mycobacterial infection.) 
Timing and extent of contact tracing investigations 
The estimated risk of transmission should guide the priority, rapidity and 
thoroughness of contact investigation. 
The following steps, summarised in the box, should be undertaken. These steps 
are described in full on the following two pages. 
1. 
2. 
Categorise the case according to the likely degree of 
infectiousness. 
Obtain a list of contacts and categorise the contacts according 
to their estimated risks. 
3. Examine all 'high risk' contacts of pulmonary TB cases first. 
4. 
5. 
Consider examination of 'medium risk' (followed by 'low risk') 
contacts of pulmonary TB cases. 
Consult with the Medical Officer of Health and NSW TB 
Coordinator, if: 
• 
• 
• 
the case works in a hospital, school, day care or long 
term care facility, 
screening is indicated for more than 25 contacts, or 
if in doubt about the priority/ extent of contact 
screening required, for any reason. 
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(1) 
(2) 
Categorise the case according to the likely degree of infectiousness 
= 
'Medium' = 
= 
direct sputum smear positive and/ or chest x-ray cavitation 
sputum culture positive and direct smear negative, no 
chest x-ray cavitation 
sputum culture and direct smear negative 
'Negligible' = extrapulmonary TB (and atypical mycobacterium) 
(As culture and identification results are not routinely available for some 
weeks, initially cases of 'medium' and 'low' infectiousness will not be 
distinguishable and atypical mycobacteria will not have been identified.) 
Obtain a list of contacts and categorise the contacts according to their 
estimated risk 
A list of close contacts, including names and addresses, should be compiled first. 
Contacts should be categorised into: 
'High risk' group = frequent, prolonged and close contact within last three 
months (or as far back as a clear history of active TB disease). This group 
includes: 
• all people living in the same dwelling 
• 
• 
relatives and friends who have frequent, prolonged and close 
contact 
any others who have spent 8 hours or more with the case in a 
closed environment. 
'Medium risk' group - frequent but less intense contact. This group includes: 
• other close relatives, friends, schoolmates and work colleagues eg 
neighbours, relatives who frequently visit the case's home. 
The 'Low risk' group includes other contacts at school (especially Primary 
Schools) or in the workplace or in clubs. However, obtaining details of'low risk' 
contacts is not necessary initially and need only be pursued if there is evidence 
of transmission in the 'high risk' and 'medium risk' groups. 
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(3) 
(4) 
(5) 
Examine all 'high risk' contacts of all pulmonary TB cases first D. 
• 'High risk' contacts of highly infectious cases should be exainined within • 
seven days of notification for child contacts and 10 days for adult 
contacts. 
• 
• 
'High risk' contacts of cases of 'medium'/ 'low' infectiousness should be 
examined within 10 days of notification (or before the case is discharged 
from hospital). 
Contacts of cases with 'negligible' infectiousness need not be examined. 
(Contacts of cases of pulmonary atypical disease should have been 
examined once, however, before identification results are available.) 
Consider examination of 'medium risk' (followed by 'low risk') contacts 
of pulmonary TB cases. 
• Only if there is evidence of transmission in the 'high risk' . 
contacts group, should screening progress to the 'medium risk' l 
1 
• 
group. 
Only if there is evidence of transmission in the 'medium risk' 
group, should screening progress to the 'low risk' group. 
'Evidence of transmission' means recent Mantoux conversion and no other 
identifiable source of infection. 
If ten or more of the closest contacts have been tested and all are Mantoux 
negative, testing of more remote contacts is usually unnecessary. 
If less than ten contacts have been tested, and all are Mantoux negative, careful 
consideration should be given to the theoretical risk of infection before stopping 
the contact investigation. 
Consult with the Medical Officer of Health in your Area/ Region and 
the NSW Tuberculosis Coordinator if: 
• 
• 
• the case works in a hospital, school, day care facility or long • 
term care facility (nursing home, hostel or prison), or 
• 
• 
screening is required for more than 25 contacts, or 
in doubt about the priority/ extent of contact tracing require 
for any reason. 
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Procedures 
Contacts who are Mantoux negative throughout follow up: 
First visit 
Mantoux test i) 
ii) chest x-ray - unless aged less than 15 years 
- chest x-ray to be reviewed by physician 
48-72 hours later 
iii) read Mantoux reaction 
Second visit - 12 weeks after 1st visit 
i) Mantoux test 
48-72 hours later 
ii) read Mantoux reaction 
Third visit - 12 months after 1st visit 
i) Mantoux test 
48-72 hours later 
ii) read Mantoux reaction 
There should be no further routine follow up. 
Contacts who are Mantoux positive at any visit must have a chest x-ray 
taken, and be referred to a physician for assessment for chemoprophylaxis (or 
chemotherapy). The alternative is annual chest x-rays for up to two years. 
Child contacts aged less than five years who are Mantoux positive 
should be referred to a physician for assessment for chemoprophylaxis (or 
chemotherapy). 
'High risk' child contacts aged less than five years who are Mantoux 
negative on the first visit should be referred to a physician and be given 
chemoprophylaxis until the 12 week Mantoux test is shown to be negative, 
unless contraindicated. 
Child contacts aged less than 16 years who are Mantoux negative and 
~av~ ~ontinuous exposure to an active case and a) cannot be placed on 
isom~z1d orb) are exposed to a case with organisms resistant to both isoniazid 
and rifampicin, should be considered for BCG vaccination prophylaxis. 
These procedures will be reviewed penr;ling results from a contac{ tracing 
survey which is currently being conducted. 
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Figure 11 : Management of Mantoux Negative Contacts 
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Figure 12 : Management of Mantoux Positive Contacts 
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3.3 MANTOUX TEST 
A. Procedure 
B. 
• 
• 
• 
• 
• 
• 
• 
Client position - Still, seated . 
Site - Upper third and middle part of anterior aspect of left forearm for 
human PPD (unless contraindicated eg large tattoo or birthmark) away 
from the veins and if possible free from hairs, scars and tattoos. Children 
with positive Mantoux reactions should be tested with avium PPD in 
their right forearm. f 
I 
Skin preparation - Swab the area with an alcohol swab. The skin must i 
be dry before injection. 
Equipment - 1ml tuberculin syringe with a 26 gauge needle 
Dose - 0.1ml of PPD (Purified Protein Derivative) tuberculin 10IU 
Method - Intradermal injection only 
Character - A "bleb" of approximately 7-Smm in diameter forms 
immediately after the injection. 
Reading the reaction 
• When? - 48-72 hours after the injection 
• What? - Induration NOT erythema 
• How? - "BALL POINT TECHNIQUE" is more accurate than the 
traditional finger tip technique of measuring induration. 
(1) Draw a line with a "medium" ball point pen from a point 2-3cm 
away from the margin of the skin test reaction towards its centre. 
Maintain skin tension by exerting slight traction opposite to the 
direction of the pen movement. 
Exert moderate pressure against the skin and move the pen 
slowly. 
(2) Lift the pen when the ball point reaches the margin of the 
indurated area and there is definite resistance to further · 
movement. 
(3) 
(4) 
Repeat the procedure from the opposite side of the reaction. 
Measure the distance between opposing lines by a calliper or 
ruler. Record in millimetres and do NOT round your reading to 
the closest 5mm. 
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Interpreting the test 
• 
• 
• 
• 
• 
Reactions are considered positive if there is induration of at least: 
(i) 5 mm: for people with HIV infection or risk factors for HIV 
infection with unknown HIV status 
' 
for recent close contacts of infectious TB cases, and 
for people with chest x-rays consistent with healed TB. 
(ii) 10mm: for others (including those who have had BCG vaccination). 
People with positive reactions should be referred for medical assessment. 
Positive reactions usually mean that the person has been infected 
with M. tuberculosis. Only 5-10% of people who have been infected are at 
risk of developing disease at some time in their lives. 
'False positive' reactions mean that the person has a positive reaction 
but has not been infected M. tuberculosis. This can occur because of: 
• 
• 
exposure to other types of mycobacterium which do not usually 
cause disease, or 
previous BCG vaccination, especially recent . 
Management would depend upon the risk of infection and should be 
assessed individually. 
'False negative' reactions mean that the person has a negative 
reaction but has been infected with M. tuberculosis. This can occur: 
• 
• 
• 
• 
• 
• 
• 
• 
before hypersensitivity develops ie during the "incubation period" 
(usually 4-12 weeks) 
with faulty technique eg poor or expired tuberculin, leaking 
syringe, injection too deep 
during advanced or terminal stages of TB 
with immunosuppression eg HIV infection 
during corticosteroid, anti-histamine or anti-inflammatory 
treatment 
with severe malnutrition, dehydration or inanition 
in the elderly, particularly with chronic illness and poor nutrition 
after an attack of pertussis (whooping cough) or measles 
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3.4 
• 
I • 
• 
• 
• 
• 
• 
HEALTH CARE WORKER SCREENING AND PROTECTION 
A high index of suspicion should be maintained to allow early identification and 
treatment of infectious patients. Effective multidrug therapy should be initiated 
promptly based on clinical and drug surveillance data. 
Infection control measures should follow established gnidelines for AFB 
isolation precautions; cleaning, disinfecting and sterilising; ensuring adequate 
ventilation; and special precautions during cough inducing and aerosol 
generating procedures. 
Policy for TB control among hospital staff should be uniform throughout NSW 
because movement of staff is common. Health care workers (HCWs) should 
carry a personal record of BCG vaccination and results of employment related 
screening from one employment to another. 
All medical, nursing, pathology, radiology and paramedical hospital staff 
should: 
• receive a Mantoux test on employment unless there is documentation of 
a positive Mantoux test, adequate treatment for disease or infection, or a 
negative Mantoux test within the previous three months, and 
• be offered BCG vaccination if Mantoux negative. 
HCWs should not commence work in a high risk area without prior adequate j 
screening. 
Whether and how often screening (Mantoux tests or chest x-rays for Mantoux 
positive workers) is undertaken during employment should depend on the 
estimated risk of infection (ie Mantoux conversion rates in cohorts of 
unvaccinated HCWs). 
• 
• 
• 
• 
HCWs should be classified into 'high', 'medium' and 'low' risk groups. 
Categorisation of potential risk should depend on a) occupational group, 
b) risk in community served by health care facility, and c) area worked 
in health care facility. 
'High risk' Mantoux negative HCWs should be periodically screened by 
Mantoux tests during employment. The frequency of screening (eg 
annually or biannually) should depend on the estimated risk of infection. 
'Medium risk' Mantoux negative HCWs should also be periodically 
screened by Mantoux tests during employment, unless the risk of 
infection is shown to be less than 1 % per annum. 
'Low risk' HCWs should not be routinely screened during employment. 
Data on skin test conversions in HCWs should be periodically reviewed so that 
infection risk can be estimated and the frequency of retesting should be altered 
accordingly. 
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• 
• 
All HCWs should be evaluated according to routine contact tracing procedures if 
they are exposed to a potentially infectious TB patient for whom adequate 
infection control procedures had not been taken . 
Documentation of the results of employment related Mantoux tests and chest x-
rays must be maintained by the health care institutions. 
PROPOSED CATEGORIES OF RISK FOR HEALTH CARE WORKERS 
1. 'High' risk category 
2 . 
3. 
• All staff working within respiratory clinics and designated chest clinics 
• Staff in bronchoscopy theatres 
• Medical, nursing staff, radiographers, physiotherapists and students who 
regularly work with TB or HIV positive patients 
• 
• 
Laboratory staff working with tuberculous material, for example, 
mycobacteria laboratory, bacteriology, cytology staff 
Mortuary staff 
'Medium' risk category 
• 
• 
• 
Other medical and nursing staff, physiotherapists, radiographers, 
paramedical staff and students involved in direct patient care not 
included in 'high' risk category 
Ambulance personnel 
Non clinical staff who are regularly in close contact with patients, for 
example, wardsmen 
'Low' risk category 
• Staff who are not routinely exposed to patients or their clinical 
specimens, for example, kitchen staff, administration and clerical staff 
Note: Occupational risk is not as much a concern in paediatric hospitals as in adult hospitals because 
children rarely cough sufficiently or have sufficient cavitatory disease to generate viable organisms. 
TB incidence in paediatric hospital HCWs probably reflects the incidence in the general population, 
rather than an occupational risk22 23. More of a concern is transmission from HCW with 
undiagnosed tuberculosis to patients . 
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3.5 
• 
• 
• 
REFUGEE SCREENING AND FOLLOW UP"' 
Refugees who are Mantoux negative throughout follow up : 
First visit 
i) Mantoux test 
ii) chest x-ray - unless aged Jess than 15 years; chest x-ray to be reviewed 
by physician 
48-72 hours later 
iii) read Mantoux reaction 
Second visit - 6 months 
i) Mantoux test 
48-72 hours later 
ii) read Mantoux reaction 
Third visit - 18 months 
i) Mantoux test 
48-72 hours later 
ii) read Mantoux reaction 
There should be no further routine follow up. Refugees should be advised to 
seek medical advice if symptoms develop. 
Refugees who are Mantoux positive at any screen must have a chest x-ray, 
and see a physician for assessment for chemoprophylaxis (or chemotherapy). 
The alternative is chest x-ray follow up for up to two years. 
Refugees with chest x-ray abnormalities should see a physician 
immediately. 
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3,6 HEALTH UNDERTAKINGS (TBU) FOLLOW UP 
(A) Migrants who have abnormal premigration chest x-rays (which may or may not 
be tuberculous in origin) and/ or have had TB treatment may be permitted 
entry to Australia if they agree to sign a Health Undertaking (TBU) to adhere 
to the following conditions: 
(BJ 
(C) 
(D) 
• 
• 
• 
• 
• 
• 
• 
report to the state/territory contact authority (in NSW, the TB 
coordinator based at Lidcombe Hospital) initially by telephone within 
one (or if advised, four) weeks of arrival 
place themselves under the authority's professional supervision 
agree to undergo any further tests (eg, Mantoux test, chest x-ray and 
medical examinations) as necessary 
agree to undergo any course of treatment which the authority directs 
inform the authority each time they change address in Australia 
throughout the period during which the authority is monitoring the 
migrants 
inform the authority whenever they are about to leave Australia and 
report to the authority on return 
inform the Australian visa office if, before departure, the proposed 
address in Australia or the travel times change 
Migrants are referred by the NSW TB Coordinator to their nearest Chest Clinic. 
Chest Clinic appointments should be made: 
• 
• 
immediately - if a) migrants have had TB treatment, or b) their pre-
migration chest x-ray abnormalities are suspicious of active TB disease, 
and 
within six months after the pre migration chest x-ray - for others . 
Routine follow up - if had previous TB treatment 
First Visit 
i) chest x-ray - to be reviewed by physician 
ii) sputum (3) for AFBs - as indicated 
iii) see physician 
Second Visit - 6 months 
i) chest x-ray - to be reviewed by physician 
ii) see physician if any changes 
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(E) 
Third Visit - 18 months 
i) 
ii) 
chest x-ray - to be reviewed by physician 
see physician if any changes 
V. ·ts annually for up to two more years Further J.S1 -
i) 
ii) 
chest x-ray - to be reviewed by physician 
see physician if any changes 
. t h d revious treat:inent Routine follow up . if no a p 
First visit 
i) 
ii) 
of Mantolll negativity or no 
Mantoux test - if documentation 
documentation of Mantoux status d d/ or if Mantoux positive and/ 
chest x-ray - if aged 15 years an . o_ver .an hest x-ray to be reviewed by 
. t· n chest x-ray susp1c10us, c or prenugra 10 
physician . 
iii) sputum (3) for AFBs - as indicated 
48-72 hours later: 
iv) read Mantoux reaction 
·t· e Mantoux reactions should be l h t x-rays or pos1 iv 
Migrants with abnorma c es_ d f h moprophylaxis or chemotherapy. 
seen by a physician to be cons1dere or c e 
. mi ation chest x-rays and no other ri_sk factors (eg 
Migrants with clear post- gr ) h uld be discharged immediately. 
Mantoux positive and recent contact s o 
Second visit - 12 months 
i) 
d over· chest x-ray to be reviewed by 
chest x-ray - if aged 15 years an , 
physician 
ii) see physician if any changes 
b alities and no other risk factors 
M. ts with stable minor chest x-ray a norm s:: be discharged after 12 months follow up. 
Third visit • 24 months 
i 
'f aged 15 years and over; chest x-ray to be reviewed by 
i) chest x-ray - 1 . 
physician 
ii) see physician if any changes 
Migrants with stable chest x-ray abnorm 
alities should be discharged after 
months follow up. . 
TBUs should be advised to seek medical attent1 
On discharge, migrants on Ch t Clinic if they develop any symptoms. 
immediately at the nearest es 
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3.7 HIV/AIDS AND TUBERCULOSIS 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The changes in cell mediated immunity, that occur in HIV related disease, 
facilitate the development of TB disease. The defect in the hypersensitivity 
component of immunity also diminishes host tissue responses, and in the late 
stages of HIV related disease, results in more easily disseminated disease and a 
different clinical picture25• 
A high index of clinical suspicion of pulmonary and extrapulmonary TB in 
patients with HN infection should be maintained and appropriate 
investigations, such as Mantoux testing, should be performed. 
HIV testing should be offered to patients with active TB, if they have a high 
risk profile for HN infection, if they have a low risk profile for TB and /or if 
they have extrapulmonary TB. Risk factors for HIV infection include history of 
homosexual contact, intravenous drug use, or migration from countries with 
high prevalence of HIV infection, for example South East Asia and Africa6 25• 
All HIV seropositive people with a Mantoux reaction > 5mm should have 
chemoprophylaxis, unless medically contraindicated. Recommended duration is 
at least 12 months with good supervision and follow up should continue 
indefinitely21• 
All HIV seropositive people with clinical AIDS or other HIV related disease 
should have a chest x-ray and be examined for extrapulmonary TB, regardless 
of the results of Mantoux testing. 
Active TB in HIV seropositive (and other immunocompromised} people should 
be treated with conventional medications but for three months longer than for 
other patients, or for a minimum of six months after sputum cultures become 
negative. Follow up of HIV/AIDS patients should continue indefinitely•. 
BCG is contraindicated in immunosuppressed patients• . 
Infection control measures for TB should be in place when investigating 
patients with HIV infection. 
Care should be taken with TB patients in health care settings, in particular 
HIV-TB coinfected people who are direct smear positive, to avoid their contact 
with immunosuppressed people (including Health Care Workers). Investigations 
and treatments which induce coughing, thereby spreading infected droplets, 
should be avoided. 
Mycobacterium isolated from HIV seropositive patients should not be assumed 
to be atypical mycobacterium, for example mycabacterial avium, until 
confirmation. 
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3.8 TUBERCULOSIS IN CHIWREN AND ADOLESCENTS"" 
Tuberculosis (TB) in children and adolescents differs markedly from TB in adults with 
regard to the following aspects. 
A. Risk of disease following primary infection 
The lifetime risk of post-primary tuberculosis disease in adults following primary 
infection is in the range of 5-10%. However, this risk is much greater in children27: 
B. 
• 
• 
• 
<1 
1-5 
11-15 
Infectivity 
year - 50% 
years - 25% 
years - 15% (females>males) 
TB in children is "primary" TB, a disease which is predominantly one of delayed 
hypersensitivity with few organisms and variable immune response. Childhood TB is 
rarely contagious except in older adolescents with cavitatory disease or laryngeal TB. 
The reasons are: 
• children with TB disease usually have a small tubercle load, 
• children very rarely have cavitating disease, and 
• children usually swallow their sputum, and have a far less effective 
cough than adults. 
C. Diagnosis 
A Mantoux reaction is considered positive28 in a child if: 
• 2: 5 mm . when child is at high risk of infection. · 
• 
• 
;;,: 10 mm • when at moderate risk of infection or BCG 2:: 5 years prior . 
z 15 mm • when at low risk of infection or BCG within 5 years . 
Risk Categories 
filGHRISK 
Contacts of infectious 
cases 
HIV infected or other 
immunosuppressed (including 
steroids) 
Abnormal chest x-ray 
MODERATE RISK 
Ethnic origin from high 
prevalence populations 
Locally identified high risk 
populations 
Children < 5 years 
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LOW RISK 
No risk factors 
l 
D. Chemoprophy1axis 
Due to the incre:35~d risk of TB disease in children, especially under the age of 5 years, 
chemopro~hy~IUO~ 18. more co~only recommended than in adults. Chemoprophylaxis, 
usually with 1soruazid alone, 1s recommended for all children and adolescents who are 
Mantoux positive but have no clinical or radiological evidence of TB. Jn the < 5 year 
age group, chemoprophylaxis is indicated if very high risk, irrespective of Mantoux 
status, until th~ ~epea~ Mantoux test is shown to be negative (three months). 
Chemo~rophyl1UOs m children, especially under the age of 5 years, should ideally be 
supervised. 
In contrast to adults, the incidence of liver toxicity from isoniazid in clilldren is 
extremely low. Liver function is evaluated only when clinically indicated and routine 
monitoring of liver function is not recommended.· ' 
E. Treatment 
It is recommended that children are treated with daily therapy with at least three 
drugs (usually isoniazid, rifampicin and pyrazinamide) for the first two months. 
Generally 2 drugs (isoniazid and rifampicin) are then used for a further 4 months and 
can be given daily or three times a week. Short course chemotherapy (6 months) has 
been shown to be effective in children, but there are insufficient data to recommend it 
for CNS, bone or joint TB infections. All treatment regimes in children should be fully 
supervised. 
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3.9 BCG VACCINATION 
BCG (Bacille-Calmette-Guerin) vaccine contains a live attenuated st~ . of 
Mycobacterium bovis - the mycobacterium has lost its vii:u1ence b~t retams _its 
antigenic property. BCG can produce immunity, overseas tnals sho~g p~otect~on 
varying from 0-75%, but rarely produces disease. In contrast, natural infection with 
virulent M. tuberculosis produces immunity, and causes disease in 5-10% of people. 
A. Indications 
BCG vaccination should be offered to Mantoux negative people who are: 
B. 
• 
• 
• 
• 
children aged less than 16 years who: 
• 
• 
• 
belong to groups with new infection rates more than 1% per year, 
have continuous exposure to cases with active disease and cannot 
be placed on isoniazid therapy, or 
have continuous exposure to cases with organisms resistant to 
isoniazid and rifampicin 
children and adults who are travelling overseas to live in a high 
prevalence country for a prolonged period (12 months or more) 
neonates from ethnic groups with a high prevalence of TB or with a 
family history of TB 
medical, nursing, pathology, radiology and paramedical hospital staff 
Contraindications 
• 
• 
Relative: 
• age > 35 years 
• pregnancy 
Absolute: 
• primary or secondary immunosuppression, ~eluding people: wi~h 
HIV infection or high risk for HIV infection where status 1s 
unknown; receiving oral corticosteroids, immunosuppressive drugs 
or irradiation 
• malignancies involving bone marrow or lymphoid systems 
• 
• 
septic skin conditions 
Mantoux reaction > 5mm 
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c. Procedure 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Mantoux reaction - Must be < 5mm. For contacts, must be < 5mm at 
the 12 week follow up. For neonates (less than one month old) BCG 
vaccination is done without perfonning a Mantoux test. 
Client position - Still, seated with head turned in the opposite direction 
of the injection site 
Site - Middle part of the left deltoid area 
Skin preparation - Swab the skin with acetone swab and make sure 
it's dry before vaccination. 
Equipment - 1ml tuberculin syringe with a 26 gauge needle 
Dosage - 0.1ml (0.075ml for neonates) 
Method - Intradermal injection ONLY ie just under the skin surface 
(NOT SUBCUTANEOUS) 
Character 
i) immediate - "bleb" of about 8mm diameter forms 
ii) 30 minutes later - "bleb" disappears 
iii) 2-3 weeks later - papule of 2-4mm forms 
iv) 2-4 weeks later - pustule forms 
v) 2-3 months later - pustule ruptures and small ulcer forms 
vi) within 3 months - scar of about 5-7mm diameter forms 
Ulcer care 
i) 
ii) 
iii) 
iv) 
Keep it open - ie. no dressings or topical treatments. 
Avoid bumps and scratclies. 
Continue normal activities - eg. swimming, sports. 
Apply a sterile gauze loosely - if necessary, for cosmetic purposes. 
Do not apply strapping near the ulcer. 
Follow up 
Repeat Mantoux tests are not indicated if a good BCG scar has formed . 
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3.10 CHEMOPROPHYLAXIS 
• 
• 
• 
• 
• 
• 
• 
• 
Unless specifically contraindicated, chemoprophylaxis should be considered for 
all high risk Mantoux positive people, such as : 
• contacts of people with TB 
• recent Mantoux converters (within two years) 
• people with medical risk factors for TB 
• 
• 
• 
• 
HIV infected people 
intravenous drug users 
people with chest x-rays suggestive of inactive TB in whom active 
disease is excluded and who have not completed treatment for TB 
others under 45 years of age (including migrants/ refugees and residents 
of long term facilities with no other risk factors). 
Chemoprophylaxis should be offered to all Mantoux negative children under five 
years of age who are close contacts of high risk (direct smear positive) people 
with TB. Prophylaxis should continue until a repeat test in 12 weeks (after 
contact is broken) is shown also to be negative. 
Chemoprophylaxis should be for a minimum of six months. Six month regimens 
are preferable to maximise compliance and minimise costs. Exceptions are those 
with HIV infection or an abnormal chest x-ray consistent with old inactive TB 
who should be treated for at least 12 months. 
Direct supervision with three times weekly short regimens is indicated for 
children aged less than five years of age and others at high risk of developing 
TB. 
Multidrug regimens should be considered for people at high risk of severe forms 
of disease who are likely to be infected with isoniazid resistant organisms. 
Isoniazid chemoprophylaxis is contraindicated for people with chronic liver 
disease or alcoholism. Where there is doubt long term surveillance is 
recommended. 
People receiving chemoprophylaxis must be reviewed at least monthly for side 
effects and to assess compliance. 
Chemoprophylactic drugs have side effects and are potentially toxic. The 
benefits of treatment must be weighed against the risks and costs, and the 
decision for treatment must be individually assessed. 
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3.11 CHEMOTHERAPY 
• 
• 
• 
• 
• 
• 
• 
• 
Chemotherapeutic regimens for tuberculosis should be chosen in accordance 
with the National Health and Medical Research Council (NHMRC) 
guidelines6• 
A high index of suspicion should be maintained to identify cases rapidly. This is 
particularly the case for patient populations who commonly present atypically, 
for example, the elderly and HIV patients. 
Effective multidrug anti-TB therapy should be initiated promptly based on 
clinical (high index of suspicion or confirmation) and drug resistance 
surveillance data. 
If drug resistance is suspected, cases should be treated as drug resistant until 
proven otherwise. Drug resistance should be suspected with a history of 
previous chemotherapy, especially if inadequately supervised or documented, or 
place of birth in Asia, Africa or Latin America. 
Drug regimens of at least six months duration are recommended for both smear 
negative and smear positive patients. In any case therapy must be long enough 
to fulfil the requirements of the given regimen. Pyrazinamide must be included 
in the first two months of any six month regimen 6. 
Chemotherapy should be fully supervised, with a three times weekly regimen, 
for all pulmonary and extrapulmonary cases. Full supervision requires the 
actual observation of drug ingestion and a written record of drug administration 
(patient and clinic held). 
The progress of smear positive patients on chemotherapy must be monitored by 
sputum examination at regular intervals until the sputum is smear negative. 
Patients who have had at least six months of supervised chemotherapy for TB 
should not be routinely followed for longer than three years after treatment is 
completed. They should be given a copy of their latest chest x-ray and advised 
about TB symptoms and urged to seek medical care immediately if symptoms 
appear . 
Active TB in HIV seropositive and other immunocompromised people should be 
treated with conventional medications but for three months longer than for 
other patients, or a minimum of six months after sputum cultures become 
negative. Follow up of HIV-AIDS patients should continue indefinitely6• 
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3,12 GUIDELINES FOR HOSPITALISATION OF ACTIVE CASES 
A. INTRODUCTION 
B. 
• 
• 
• 
• 
Transmission of infection is more likely to occur in poorly ventilated and 
overcrowded conditions, and infection of family contacts is the most 
common. The risk of infection is related more to the bacteriological 
status of the patient rather than to the intimacy of contact, so that 
infection may occur when contact has not been prolonged or close. 
Indirect contact through contaminated articles is extremely rare, as is 
direct invasion through mucous membranes or breaks in the skin. 
Appropriate antimicrobial therapy reduces communicability within a few 
weeks; some untreated or inadequately treated patients may be 
intermittently AFB sputum positive for years. 
Closed extrapulmonary TB is not infectious. There is a risk of 
transmission in the presence of a tuberculous discharge. 
HOSPITAL ADMISSION 
• 
• 
Patients diagnosed or suspected of having active TB should be admitted 
to hospital to: 
• confirm the diagnosis, 
• 
• 
mm1m1se further spread during the period of high 
communicability, and 
initiate the treatment and assess the patients' tolerance of 
medication. 
Patients with active TB should remain in hospital as long as their 
sputum is positive for AFB on direct examination. Three specimens 
collected at 24 hour intervals should be negative for AFB. Exceptional 
circumstances may justify earlier discharge. A longer time in hospital 
may be required under the following circumstances : 
• 
• 
continued infectivity due to severe disease with cavitation or 
medication failures, or 
social situation that may lead to non-compliance and disease 
transmission. 
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c. PATIENT MANAGEMENT 
Isolation procedures 
• 
• 
• 
• 
• 
• 
People with direct sputum smear positive TB should be treated with 
appropriate anti-TB drugs in a single room for at least two weeks. Acid 
fast bacilli (AFB) precautions should be continued until the AFBs are 
clearing from sputum specimens and there is a significant clinical 
improvement. 
People with infectious TB should be isolated from immunocompromised 
persons, until sputum is negative for AFB or no sputum is being 
produced. 
Single rooms, with external ventilation (negative pressure), are 
necessary for people with infectious TB. Patients may leave their rooms 
and use hospital grounds. 
The following equipment is needed for each room: masks, thermometer, 
garbage bag holder with contaminated waste bag. 
The followiing additional equipment is needed if a discharging lesion or 
sinus is present: plastic aprons/gowns and disposable gloves. 
Separate crockery, cutlery and bed linen are not required, as tubercle 
bacilli do not survive for long outside the body and are killed by normal 
machine dishwashing and laundering procedures. 
• Soiled linen should be treated as contaminated. 
Personal hygiene 
• Patients should be instructed in personal hygiene especially the need to 
cover the mouth and nose when coughing or sneezing and the careful 
handling and disposal of sputum. 
Waste Disposal 
• Sharps should be disposed as usual. 
• 
• 
• 
Sputum should be collected in disposable containers, with lids which can 
be SECURED . 
Patients should be instructed to cough and sneeze into tissues, which 
should be disposed of in plastic bags . 
Body Substance Isolation Precautions apply as normal to handling of 
urine etc. 
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Laboratory Specimens 
• 
• 
Laboratory specimens should be: 
• well sealed with no contamination of the outside of the bottle, 
• transported immediately to laboratory in a sealed biohazard bag. 
A yellow sticker should be placed on the request form which is placed in 
the separate sleeve of bag. 
Visitors 
• 
• 
• 
Visitors should wash hands on entering and leaving the room . 
Visitors do not need to wear gowns or masks. 
Children other than the patient's own children should be discouraged 
from visiting. 
Transport of Patients 
• Patients should be adequately clothed, and required to wear a mask only 
to cover mouth and nose with tissue while coughing or sneezing. 
Cleaning of Room 
• TB patients' rooms should be cleaned daily with neutral detergent and a 
disposable cloths. The disposable cloths should be discarded as 
contaminated waste. 
• TB patients' rooms should be cleaned after other rooms have been 
attended. 
D. NOTIFICATION OF CASES 
• Tuberculosis is notifiable under the Public Health Act 1991. It is 
notifiable as tuberculosis by Medical Practitioners pursuant to Section 
14, by Hospital Chief Executive Officers pursuant to Section 69 and as 
mycobacterial infection by laboratories pursuant to Section 16 of the Act. 
Notifications must be made to the Public Health Unit using Notifiable 
Disease certificates which are available from the Public Health Units. 
• The TB sister at the Chest Clinic serving the area where the patient 
lives, should be contacted as soon as possible after admission, and 
certainly before discharge, to discuss arrangements for supervision of 
post discharge treatment of the patient and examination of contacts. 
• All patients should have supervised chemotherapy throughout 
hospitalisation and after discharge from hospital. 
46 
E. STAFF PROTECTION 
• 
• 
• 
• 
• 
• 
Staff involved in the management of diagnosed cases of tuberculosis are 
at no greater risk of contracting the disease than other staff in 
hospital. In fact, there is a greater risk of contracting tuberculosi: 
from undiagnosed cases. 
All medical and nursing staff, as well as pathology, radiology and 
paramedical staff in a hospital should have a Mantoux test at the 
beginning of employment, and be offered B.C.G. vaccination if Mantoux 
negative. 
Immunocompromised staff members should not work on wards where 
there are active cases of TB. 
Mantoux negative staff on wards with active cases of TB should have 
regular screening with Mantoux tests (see Chapter 3.4). 
Staff should be screened according to routine contact tracing procedures 
after exposure to potentially infectious cases of TB for whom adequate 
infection control measures had not been taken. 
Universal precautions should be taken. Specifically: 
• 
• 
Masks should be put on when patient requires close nursing 
attention only. 
Body substance isolation precautions apply when handling 
sputum or other infected body substances. 
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3.13 BACTERIOLOGICAL STUDIES IN TUBERCULOSIS29 
The ultimate success of any modern TB Control Program will be conti~gent on the 
availability of high quality laboratory services. Important functions of the 
mycobacteriology laboratory are: 
• 
• 
• 
• 
• 
microscopy 
culture 
speciation of isolates 
drug susceptibility testing 
statistics 
• training 
• research 
A. Level of laboratory service • mycobacteriology 
Obviously, not all pathology laboratories need to provide such services. US au~horities 
have proposed a three tiered 'classification' sys~em . for labs carrymg out 
mycobacteriological tests. Australian labs can be categonsed m much the same way, as 
set out below. 
Levell 
Level II 
Level III 
This category covers the majority of 'general' bacteriology ~abora~ories (~s 
would be found in hospitals) and smaller private pathologists. Direct acid 
fast microscopy (AFM) should be available, but culture for MTB should 
not be attempted. Specimens are referred to a higher level facility for 
both confirmatory microscopy as well as culture. 
This category covers the larger laboratory as would be found in certain 
metropolitan and provincial hospitals, and some private patholo_gy 
laboratories·. Such facilities perform both AFM and mycobactenal 
culture. Species identification is not generally performed at this Level, 
although this situation might change due to new technology such as 
radiometric culture and DNA probes. Even so, it is imperative that all 
new isolates of MTB as well as any likely pathogenic atypical 
mycobacteria be forwarded to a Level III facility for further testing. 
Laboratories in this category will generally be large reference units such 
as now exist in Brisbane, Sydney, Melbourne, Adelaide and Perth. In 
addition to AFM and culture, Level III labs provide drug susceptibility 
tests, and full speciation of isolates. Support should also be available to 
lower level labs in the form of training, provision of reference methods 
and mycobacterial strains. Statistics, particularly those dealing with new 
diagnoses of TB, should be collated and provided to public health 
authorities. Level III labs should also be involved in the development or 
evaluation of new tests such as those involving molecular procedures. In 
the future, seruni drug assays might be performed on patients being 
treated for certain atypical mycobacterial infections. · 
Note: It would be the opinion of most expert mycobacteriologists that culture should ~ot be undert~ken in 
situations where the number of samples received is small, and/or the frequency of pos1t1ves (MTB) 1s v~ry 
low. In such situations, quality assurance procedures assume greater importa~ce. As a gmde, laborato1:es 
receiving Jess than around 40 routine samples per week should be discouraged from performing 
mycobacterial culture. There would be exceptions, e.g. in the case of a laboratory dealmg with regular 
requests for blood culture in patients with AIDS. 
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B. . Quality assurance 
It is essential that laboratories performing diagnostic mycobacteriology at any level 
carry current NATA accreditation for such procedures by NATA. In addition, there 
should be continued efforts to monitor proficiency through participation in quality 
assurance programs (QAP) such as those conducted by the following: 
• 
• 
• 
• 
RCPA (Royal College of Pathologists of Australia) 
CAP (College of American Pathologists) 
ASM (Australian Society for Microbiology) 
State Tuberculosis Reference Laboratories. 
The major of Australian pathology laboratories subscribe to the RCPA Microbiology 
QAP, which regularly includes a test for a laboratory's capability to demonstrate (and 
recogiuse) mycobacteria in specimens and in cultures. It must be stressed that 
satisfactory completion of this exercise should not be taken as proof of proficiency in all 
facets of mycobacteriology. The RCPA QAP does, however, contribute to the general 
awareness of mycobacteria as pathogens. 
C. Standards 
It has been a goal of the Special Interest Group in Mycobacteriology (within the 
Australian Society for Microbiology) to standardise methods in use in major diagnostic 
mycobacteriology labs throughout Australia. Although some degree of success can be 
claimed, each of the reference labs have long established protocols, and most are 
reluctant to make major changes. Nevertheless, it can be said that methods in use are 
similar and have comparable sensitivity and outcome, as shown by the results of 
collaborative trials. 
Microscopy 
Should be performed on all specimens (blood would be optional), using Ziehl-Neelsen 
and/or fluorochrome staining. Positive reports should make some attempt quantitation 
of the number of AFB present. 
Culture 
Should be performed on all specimens, using either the BACTEC system, or egg based, 
or agar media or combinations of these. Certain species such as M bovis, M 
haemophilum, M marinum have special requirements in media and/or temperature of 
incubation, and must be adequately catered for. BACTEC 13A medium is 
recommended for blood cultures. All cultures should be read at least weekly for at 
least 6 weeks. 
Identification 
Level III facilities should have the expertise to identify all human pathogens. 
• MTB Complex: identify by recogiused criteria, such as niacin 
production, nitrate reduction, cord formation, lack of growth at room 
temperature, drug susceptibility. Differentiation within the MTB 
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complex can also be achieved through such tests. Commercial DNA 
probes can provide more rapid results and are acceptable substitutes, 
but will not provide speciation within the MTB complex. 
• Atypical Mycobacteria: identify all isolates likely to be pathogens, i.e. 
repeat isolates from sputum, isolates from sterile sites, tissues, 
wounds. Authoritative texts provide adequate reference sources fro 
procedures and identification strategies. 
Susceptibility 
Should be performed only in Level III facilities. 
D. 
• 
• 
MTB complex: test all initial isolates, as well as repeat isolates from 
relapse cases and 'treatment failures', for susceptibility to at least 
isoniazid, ethambutol, rifampicin and pyazinamide. The radiometric 
(BACTEC) method is recommended. 
Atypical Mycobacteria: The value of susceptibility tests on a low-
growing atypical mycobacteria remains a topic of debate, although it is 
likely that more conclusive data will emerge in the near future. As a 
general policy, drug susceptibility testing of slow-growing species such 
as M avium comJJlex cannot be justified. Some species (e.g. M kansasii) 
are so uniform in their susceptibility patterns that there is nothing to 
be gained from testing every isolate. Rapid growing species such as M 
fortuitum should be tested against a range of drugs such as 
tetracyclines, aminoglycosides, sulphonamides, by disc diffusion or disc 
elution. 
Technological developments in mycobacteriology 
The development of the semiautomated radiometric technique (BACTEC) has been 
partly responsible for a trend towards decentralisation of mycobacteriological 
laboratory services. Data accumulated from numerous centres in the past decade has 
confirmed its reliability, sensitivity, and reproducibility. A noteworthy virtue of the 
BACTEC system is that it provides a safe, efficient procedure for culturing blood from 
patients infected with HIV. It also includes options for (i) rapid differentiation of MTB 
complex and atypical mycobacteria (4 days), and (ii) rapid determination of drug 
susceptibility (4-7 days). Further, commercial probe kits can be applied directly to the 
BACTEC cultures for speciation. Thus, BACTEC can shorten significantly the interval 
between receipt of specimen and issue of results. 
The new DNA amplification procedures such as PRC promise to revolutionise 
diagnostic mycobacteriology. Numerous publications have demonstrated the potential 
value of such assays, but they remain unproven in prospective clinical studies. 
Commercial PCR based tests for mycobacteria are likely to be released in the near 
future. Potentially, these will offer further opportunity for the smaller lab to perform 
high level mycobacteriology, and might bring about further change in 
recommendations as to which laboratories perform what tests. 
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APPENDIX 1 CASE DEFINITIONS 
TUBERCULOSIS 
Tuberculosis is notifiable under the Public Health Act 1991 It · tifiabl 
tb cul· b Mdial . 1sno eas 
u er . os1s Y e c Practitioners pursuant to Section 14, by Hospital Chief 
Executiv~ Officers pursuant to Section 69 and as mycobacterial infection b 
laboratories pursuant to Section 16 of the Act. Tuberculosis case d fi ·t· Yao 
follows : e m 10ns are as 
Clinical Criteria 
• 
• 
• 
Signs and symptoms compatible with pulmonary tuberculosis with an 
abnormal, unstable chest x-ray, or ' 
Signs and symptoms compatible with extrapulmonary tuberculosis, or 
Evi~ence of disease where treatment, with two or more 
antituberculous medications, has been prescribed. 
Laboratory Criteria 
• Isolation of Mycobacterium tuberculosis, Mycobacterium bovis or 
Mycobacterium africanum from a clinical specimen, or 
• Demonstration of acid fast bacilli in clinical specimen when a culture 
h_as not been or cannot be obtained, in a person suspected of having 
signs and symptoms compatible with tuberculosis31. 
NEW/ CHRONIC/ REACTIVATED CASES 
Relapse or reactivation 
• Proven clinic~ly, radiologically or bacteriologically following at least 
12 months. qUie~cence after full chemotherapy has stopped and cure 
was bactenologically proven. 
New case 
• Never received antiTB treatment for more than one month . 
Treatment failure 
• Still direct smear positive at five months or more after the start of 
chemotherapy for a newly diagnosed case of TB. 
51 
Returning defaulter 
• Interrupted treatment for more than 2 months after completing the 
first month of chemotherapy, returned to treatment and was found to 
be direct smear or culture positive. 
Chronic case 
• Still discharging AFB after completing a retreatment regimen under 
supervision. 
CAUSE OF DEATH 
Deaths caused by TB 
• Principal cause of death was TB. 
Deaths contributed to by TB 
• Principal cause of death is not TB but TB may be a contributing factor . 
Deaths incidental to TB 
• Principal cause of death was not TB, but TB was present at time of 
death. 
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APPENDIX 2 MINIMUM DATA REQUIREMENTS FOR TB CASE FINDING 
AND MANAGEMENT 
• age, sex, body weight 
• date of onset, date of diagnosis, date of notification 
• Chest Clinic/ AHS or Region - commencing treatment/ supervising treatment 
• postcode of residence 
• ethnicity - Asian, Australian Aboriginal, Caucasian, Pacific Islander, Other 
• immigration status - refugee, SHP, etc 
• country of birth, length of residence in Australia - date of arrival 
• HIV status - PIN/lJ; BCG status - YIN/lJ 
• diagnosis - microscopy (PIN), culture (PIN), Mantoux tests (mm, PIN), other 
skin test (mm, PIN), histology (PIN), radiological signs, clinical signs, other 
• pathogen 
• site of disease - Pulmonary/ Extrapulmonary/ Both - pulmonary, pleurisy with 
effusion, pericarditis, peritonitis, laryngeal/ endobronchial, lymphadenitis, 
skeletal, genitourinary, meningeal, ocular, gastrointestinal, adrenal, cutaneous, 
miliary, other 
• past history of disease and anti-TB treatment - new case/ relapse/ 
treatment failure/ returning defaulter/ chronic case (see Appendix 1 for 
definitions); previous anti-TB treatment - Y (one or more months)/ N - dates 
commenced, stopped, completed 
• refugee screening program/THU - attended initial visit, attended follow ups, 
follow up completed - dates 
• source of diagnosis - chest clinic (self referral), hospital, specialist, GP, TBU, 
refugee screening program etc; transfer - YIN 
• medications (15 possibilities plus 3 other) - dates initiated and completed -
codes for standard regimens eg 2HRZ/4HR3; supervision - YIN 
• drug sensitivities - four drugs 
• treatment outcome - bacteriology smear results - dates; regularity of drug 
intake - interruption of therapy, resumed therapy, ceased therapy, lost to follow 
up - dates; died during treatment - YIN - cause of death TB or other (see 
Appendix 1 for definitions) 
• contacts - relational file; other public health action 
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APPENDIX 3 SURVEILLANCE AND PROGRAM EVALUATION -
INDICATORS 
A. 
B. 
Monitoring active disease 
• 
• 
• 
• 
• 
• 
Active TB incidence rates - Age, sex and ethnicity specific rates 
should be estimated, particularly active TB incidence rates in children 
less than five years of age. 
Smear positive active TB incidence rates - Smear positive cases 
provide the most important epidemiological information because smear 
positive cases are the most infectious; they provide a highly specific 
core index of cases diagnosed with certainty; they are the most globally 
comparable; and case holding and treatment outcomes of these 
patients provides the best measures of program efficacy
32
• 
TB-HIV coinfection rates - Although TB-HIV coinfection does not 
appear to be a problem in NSW at present, there is a need to carefully 
monitor the situation. 
TB mortality rates - The value of mortality data as an indicator of 
the TB problem is limited in industrialised countries because effective 
chemotherapy has vastly reduced deaths from TB
32
• Careful analysis of 
mortality trends, however, contributes to the monitoring of diagnostic 
and treatment standards. 
TB meningitis incidence rates in children under 5 years of age -
This is a useful indicator of the intensity of M tuberculosis 
transmission and thus also of the effectiveness of case finding and 
treatment32• It is also important as a measure of the need for BCG 
vaccination of neonates. 
Drug resistance rates - Drug sensitivity testing for primary and 
acquired resistance provides useful information not only on the 
epidemiological situation, but also on the effectiveness of the 
treatment program. 
Monitoring infection 
• 
• 
Annual incidence (or risk) of infection - Direct estimates require 
periodic screening of cohorts of unvaccinated people. 
Infection prevalence - Prevalence estimates among unvaccinated 
children, from Mantoux testing surveys, can be used to derive a crude 
estimate of the risk of infection in the population. 
54 
c. 
I»1:ection data are obtained from Mantoux screening. Screening serves a number 
of unportant roles, by providing: 
• 
• 
• 
• 
epi~e~iologic data for assessing the extent of the TB problem (and 
penodi~ surv~ys provide trends of infection in the population), 
data with which to assess the value of continued screening 
identification of people who would benefit from prophylacti~ or curative 
therapy, and, 
the opportunity to increase the awareness of high risk populations 
about TB and how to access TB Services. · 
In prac~ce there are limitations to the monitoring of TB infection in the general 
populat10n because: . . 
• 
• 
• 
• 
• 
• 
significant resources are required, 
large sample sizes are needed in low prevalence populations to obtain 
reliable estimates, 
the predictive value of screening tests declines with decreasing 
prevalence, 
in terms of ide~ti~ng individuals who would benefit from prophylactic 
therapy screerung 1s only productive and cost effective in populations 
with a high prevalence ofTB6, and 
B~G vac~nati?n ~~ make the Mantoux test difficult to interpret and 
ummmumsed individuals may not be representative of the general 
population. 
Mantoux conversion rates in contacts - This reflects the current 
transmission of TB in the population. 
Evaluating case finding and management' 
• 
• 
• 
Case detection ratio · Proportion of expected cases that were 
rep.ort~d. This reflects the intensity and the extent of the case finding 
activities. The calculation requires prior knowledge of the annual risk 
of infection; it may not be valid when the annual risk of infection is 
low"'. 
Delay in diagnosis - Time after onset until diagnosis . 
Delay until treatment - Time after diagnosis untii treatment 
commenced. 
CaJeulation of tb~ indicators .by coho~ anaJy~is i9 the most infomtBtive (or evaluating the case holding and treatment program. The 
cohort ~houl~ consist of aJI pat1e11ts registered 1n a given ti.Ine i.tat.fi!rval (eg three or 12 months). Tb1:1c duration of the interval between 
~he i~Stl'8~1on of the cases an~ the a~alysis is cb.osen so that all patients can have completed the pregcribed treatment and foUow· 
JI formation bas become avruJable (re the duration of the treatttaent regi!Jlen plus another three tnontbs). 
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• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Appropriate drug regimen ratio · Proportion of active cases 
initiating treatment with appropriate and/ or standardised multidrug 
regimen. 
Supervised therapy ratio · Proportion of active cases on supervised 
therapy. 
Bacteriologic conversion ratio · Proportion of cases with 
bacteriologic conversion of sputum within three months of commencing 
therapy33• 
Drug continuity ratio - Proportion of active cases who have taken 
chemotherapy continuously for the first six months of treatment; 
Proportion interrupted therapy; Proportion stopped therapy33• 
Drug completion ratio - Proportion of active cases completing 
therapy within six/ nine/ 12 months32 33• 
Treatment failure ratio - Proportion who are still sputum smear 
positive at five months or more after the start of chemotherapy32• 
Defaulter ratio - Proportion who interrupted treatment for more than 
two months after completing one month of chemotherapy, returned to 
d b 't' 32 treatment and were faun to e smear pos1 1ve . 
Cure ratio . Proportion of patients whose cure was bacteriologically 
documented. This is considered the best and most accurate indicator of 
treatment program perlormance32• A high cure ratio indicates that 
both bacteriological follow up was properly done and that sputum 
conversion occurred. 
Relapse rates . Proportion of cases who have been previously declared 
cured (bacteriologically) after completing full treatment more than 12 
months before. 
Case fatality ratio - Proportion of patients who died of any cause 
during the course of treatment. It is an indicator of the perlormance of 
the treatment program but also obviously provides information on the 
TB problem32• However, it should be interpreted carefully in low 
incidence countries. 
Case finding and chemotherapy 'impact' indicators34 : 
A summary 'impact' indicator can be calculated from the four 
indicators: 
new cases diagnosed new cases put on CT treatment completed cases rendered negative 
IMP ACT - ·-------··--·------·--· • --------·-------------- -·----------------
existing cases new cases diagnosed cases put on treatment treatment completed 
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Evaluating case prevention 
Screening of contacts 
• 
• 
• 
• 
Delay in contact · Time from index case diagnosis until close contacts 
examined. 
Follow up ratio · Proportion of contacts examined. 
Infection rate · Proportion of located contacts with new infections . 
Prophylactic therapy ratio · Proportion of contacts with new 
infections who are prescribed prophylactic treatment. 
• 
Active disease prevalence - Proportion of located contacts with active 
disease. 
Screening of other high risk groups 
• 
• 
Infection prevalence · Proportion of various populations with infections 
detected by screening . 
Prophylactic therapy ratio - Proportion with infections who are 
prescribed prophylactic treatment. 
• 
Active disease prevalence · Proportion with active TB disease detected 
by screening. 
Chemoprophylaxis 
• 
• 
Drug continuity ratio · Proportion completed six continuous months of 
medications 
Supervised therapy ratio - Proportion on supervised therapy 
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• APPEND1X4 
LEGAL ASPECTS OF TUBERCULosrs CONTROL 
A. Public Health Orders 
• Public health orders may he made under Part 3, Division 6 of the Public 
Health Act 1991 by an authorised Medical Practitioner ifs/he is satisfied that the person is: 
• suffering from tuberculosis and 
• is behaving in a way that is endangering, or is likely to endanger, 
the health of the public because the person is suffering from the disease. 
• A public health order must require the person to whom it applies to do any one or more of the following: 
• refrain from a specified conduct 
• undergo specified treatment 
• undergo counselling by a specified person or by one or more 
persons belonging to a specified class of persons 
• submit to the supervision of a specified person or one or more 
persons belonging to a specified class of persons 
• undergo specified treatment and be detained at a specified place 
while undergoing the treatment. 
• An order must indicate: 
• the circumstances Purporting to justify making the order and 
• the length of time it is to remain in force (up to 28 days). 
• Where the circumstances justify continuing the order past 28 days, than 
an application may be made to the District Court to extend the order for up to a further six months. 
• It is an offence to contravene an order and the person may be 
apprehended by the police for such a contravention. 
• It is also an offence to improperly release a person being detained under an order. 
• An appeal to the District Court may be made against the order. 
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